

Clinical Oversight Review Board (CORB) Criteria for Prescribing Crizanlizumab-tmca (Adakveo)

Non-Formulary **crizanlizumab-tmca (Adakveo)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **crizanlizumab-tmca (Adakveo)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has diagnosis of sickle cell anemia or sickle beta thalassemia (documented by hemoglobin electrophoresis)
- Patient is at least 16 years of age
- Currently taking maximum tolerated dose of hydroxyurea (35 mg/kg or dose limited by absolute neutrophil count (ANC) $\leq 1,000/\mu\text{L}$ or platelets $\leq 100,000/\mu\text{L}$) for at least 3 months, unless history of intolerance or patient declines use due to potential adverse effects
- Prior trial of L-glutamine for at least 3 to 6 months before considering crizanlizumab-tmca
- Two or more sickle cell pain crises within prior 12 months requiring intervention (hospitalizations, emergency department or urgent care visits)
- Using appropriate contraception if of childbearing potential
- ALT $< 3x$ upper limit of normal (ULN) or direct bilirubin < 2 mg/dL
- GFR > 45 mL/min/1.73 m²